Trial Profile
A retrospective cohort study to assess the effectiveness of apixaban compared to warfarin for the prevention of recurrent-VTE and cardiovascular-diseases (CVD) in patients with Venous Thromboembolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary)
- Indications Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 24 Jan 2020 Results published in the American Journal of Health-System Pharmacy
- 24 May 2018 New trial record
- 23 May 2018 Results presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research